Prestige Biologics Order Backlog Tops KRW 30 Billion, Marking Growth Milestone
[Song Young-doo, Edaily Reporter] Prestige Biologics, a contract development and manufacturing organization(CDMO) for biopharmaceuticals, said Sunday its cumulative order volume has surpassed KRW 32 billion, a record high since the company’s founding.
It is the first time the company’s annual orders have exceeded KRW 30 billion.
The figure represents more than a 1,500% increase compared to last year’s revenue of KRW 2.1 billion.
뉴스픽의 주요 문장 추출 기술을 사용하여 “이데일리” 기사 내용을 3줄로 요약한 결과입니다. 일부 누락된 내용이 있어 전반적인 이해를 위해서는 본문 전체 읽기를 권장합니다.
